share_log

Positive Earnings Growth Hasn't Been Enough to Get PKU HealthCareLtd (SZSE:000788) Shareholders a Favorable Return Over the Last Five Years

Positive Earnings Growth Hasn't Been Enough to Get PKU HealthCareLtd (SZSE:000788) Shareholders a Favorable Return Over the Last Five Years

在過去五年中,正收益增長不足以讓北京大學醫療保健有限公司(深圳證券交易所代碼:000788)股東獲得可觀的回報
Simply Wall St ·  04/26 18:19

This week we saw the PKU HealthCare Corp.,Ltd. (SZSE:000788) share price climb by 14%. But that doesn't change the fact that the returns over the last five years have been less than pleasing. In fact, the share price is down 26%, which falls well short of the return you could get by buying an index fund.

本週我們看到北京大學醫療保健有限公司(深圳證券交易所代碼:000788)的股價上漲了14%。但這並不能改變這樣一個事實,即過去五年的回報並不令人滿意。實際上,股價下跌了26%,遠低於購買指數基金所能獲得的回報。

On a more encouraging note the company has added CN¥387m to its market cap in just the last 7 days, so let's see if we can determine what's driven the five-year loss for shareholders.

更令人鼓舞的是,該公司的市值在過去的7天內就增加了3.87億元人民幣,因此,讓我們看看我們能否確定導致股東五年虧損的原因。

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

用本傑明·格雷厄姆的話來說:從短期來看,市場是一臺投票機器,但從長遠來看,它是一臺稱重機。研究市場情緒如何隨着時間的推移而變化的一種方法是研究公司股價與其每股收益(EPS)之間的相互作用。

While the share price declined over five years, PKU HealthCareLtd actually managed to increase EPS by an average of 9.4% per year. So it doesn't seem like EPS is a great guide to understanding how the market is valuing the stock. Or possibly, the market was previously very optimistic, so the stock has disappointed, despite improving EPS.

儘管股價在五年內下跌,但PKU HealthcareLtd實際上設法做到了 增加 每股收益平均每年增長9.4%。因此,每股收益似乎不是了解市場如何估值股票的好指南。或者,市場此前可能非常樂觀,因此儘管每股收益有所改善,但該股還是令人失望。

Due to the lack of correlation between the EPS growth and the falling share price, it's worth taking a look at other metrics to try to understand the share price movement.

由於每股收益增長與股價下跌之間缺乏相關性,值得一看其他指標,以了解股價走勢。

The revenue fall of 2.2% per year for five years is neither good nor terrible. But if the market expected durable top line growth, then that could explain the share price weakness.

五年來收入每年下降2.2%,這既不是好事也不是很糟糕。但是,如果市場預計收入將持續增長,那麼這可以解釋股價疲軟的原因。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

公司的收入和收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。

earnings-and-revenue-growth
SZSE:000788 Earnings and Revenue Growth April 26th 2024
SZSE: 000788 2024年4月26日收益和收入增長

This free interactive report on PKU HealthCareLtd's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想進一步調查該股,這份關於PKU HealthcareLtd資產負債表實力的免費互動報告是一個很好的起點。

A Different Perspective

不同的視角

While the broader market lost about 13% in the twelve months, PKU HealthCareLtd shareholders did even worse, losing 23%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 5% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Before deciding if you like the current share price, check how PKU HealthCareLtd scores on these 3 valuation metrics.

儘管整個市場在十二個月中下跌了約13%,但PKU HealthcareLtd股東的表現甚至更糟,下跌了23%。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本發展。遺憾的是,去年的業績結束了糟糕的表現,股東在五年內每年面臨5%的總虧損。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。在決定是否喜歡當前股價之前,請查看PKU HealthcareLtd在這三個估值指標上的得分。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,請看一下我們預計收益將增加的這份免費公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論